GA-68 DOTA-TOC of Somatostatin Positive Malignancies
Status:
Terminated
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography
(PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging
patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to
somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a
special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed
pictures of areas where material accumulates in the body. Diagnostic procedures, such as
gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor
positive tumors and help plan the best treatment.